Diagnosing Dementia and Assessing Its Severity

Core Diagnostic Criteria for Dementia

Dementia is diagnosed when cognitive or behavioral symptoms interfere with ability to function at work or usual activities, represent a decline from previous functioning, and are not explained by delirium or major psychiatric disorder, as recommended by the American Academy of Neurology 1, 2
Key cognitive domains to assess include memory, executive function, visuospatial abilities, language functions, and personality and behavior changes, according to the American Psychiatric Association 1, 2

Diagnostic Assessment Tools

The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) are widely used cognitive screening tools with high sensitivity and specificity for moderate dementia, as stated by the National Institute on Aging 3
The Clock Drawing Test is a useful supplementary test for cognitive screening, as recommended by the American Geriatrics Society 3, 4

Diagnostic Workup

Anatomical neuroimaging is recommended in most situations, especially with onset of cognitive symptoms within past 2 years, unexpected decline in cognition/function, recent significant head trauma, unexplained neurological manifestations, or significant vascular risk factors, as suggested by the American College of Radiology 5
MRI is preferred over CT, especially for detecting vascular lesions, according to the American Heart Association 5

Assessing Severity of Dementia

Severity assessment should be based on degree of cognitive impairment, level of functional impairment in daily activities, and presence and severity of behavioral symptoms, as recommended by the Alzheimer's Association 6, 5
The MMSE is recommended as a primary tool for tracking cognitive changes over time, with assessment occurring every 6-12 months, as suggested by the National Institute on Aging 6, 5

Special Considerations

For patients with subjective cognitive decline, conduct appropriate diagnostic workup to identify reversible causes and obtain reliable informant information about changes in cognition, function, and behavior, as recommended by the American Academy of Neurology 7, 4
Differentiation of mild cognitive impairment from dementia rests on whether there is significant interference with daily functioning, as stated by the American Psychiatric Association 1, 2

Tracking Response to Treatment and Disease Progression

Use a multi-dimensional approach that includes assessment of cognition, functional autonomy, behavioral symptoms, and caregiver burden, as recommended by the Alzheimer's Association 4, 6, 5
All domains must be evaluated at least annually, with more frequent assessment for patients with behavioral symptoms, as suggested by the National Institute on Aging 4, 6

Dementia Workup and Management

Initial Assessment

A patient with new onset forgetfulness and a SLUMS score of 12 requires a comprehensive dementia workup, as this presentation strongly suggests dementia rather than mild cognitive impairment, according to the Alzheimer's Association 8
Obtain corroborative history from a reliable informant about changes in cognition, function, and behavior, which has prognostic significance, as recommended by the American Academy of Neurology 9
Use structured scales to assess objective cognition, informant-reported cognition/function, and behavior, such as the MoCA, Clock Drawing Test, ECog, IQCODE, Lawton Instrumental Activities of Daily Living Scale, MBI-C, and NPI-Q, as suggested by the Alzheimer's Association 9

Diagnostic Workup

No cited facts are available for this section

Cognitive Assessment

Additional cognitive testing may help characterize the pattern of deficits, and neuropsychological testing can establish the extent and severity of cognitive impairment objectively, according to the National Institute on Aging 10

Functional Assessment

Assess the impact on instrumental activities of daily living, such as ability to manage finances, medication management, transportation abilities, household management, cooking, and shopping abilities, as recommended by the American Geriatrics Society 9

Treatment Planning

No cited facts are available for this section

Follow-up and Monitoring

Schedule follow-up visits every 6-12 months to track disease progression, and use a multi-dimensional approach to monitor cognition, functional autonomy, behavioral symptoms, and caregiver burden, as recommended by the Alzheimer's Association 9
Provide information on the World Health Organization recommendations for dementia prevention, which includes promoting physical activity, social engagement, and cognitive stimulation, as suggested by the World Health Organization 9

Initial Dementia Workup Protocol

Step 1: Comprehensive History and Cognitive Assessment

The American College of Radiology and Alzheimer's and Dementia society recommend obtaining a thorough medical history and cognitive assessment with standardized tools, including collecting corroborative history from a reliable informant about changes in cognition, function, and behavior using structured tools like AD8 or Alzheimer's Questionnaire 11
Documenting baseline functioning and comparing with current functioning to establish decline is recommended by the Mayo Clinic Proceedings 12, 13

Step 2: Laboratory Testing for Reversible Causes

The Mayo Clinic Proceedings recommend thyroid function tests (TSH, free T4), Vitamin B12 and folate levels, and HIV testing if risk factors are present 14

Step 3: Structural Neuroimaging

The Journal of the American College of Radiology recommends MRI over CT, especially for detecting vascular lesions 15

Step 4: Assess for Common Contributors to Cognitive Impairment

The Mayo Clinic Proceedings recommend evaluating for sleep disorders, particularly sleep apnea, assessing sensory deficits (hearing loss, vision loss), and evaluating for pain and mobility problems that may affect function 14

Step 5: Diagnostic Formulation

The Alzheimer's and Dementia society recommend integrating information about risk profile, history of symptoms, and examination findings to determine whether cognitive-behavioral syndrome is present 11

Common Pitfalls to Avoid

The Alzheimer's and Dementia society recommend not overlooking medical conditions that can influence biomarker interpretation 16

Comprehensive Psychiatric Evaluation in Dementia Patients

Essential Components to Document

The American Academy of Neurology recommends documenting a comprehensive psychiatric evaluation in dementia patients using validated structured assessment tools across three mandatory domains: neuropsychiatric symptoms, functional status, and cognitive performance, combined with corroborative informant history 17
The Alzheimer's Association suggests using the Neuropsychiatric Inventory-Questionnaire (NPI-Q) or Mild Behavioural Impairment Checklist (MBI-C) to systematically document behavioral and psychological symptoms 17
The American Geriatrics Society recommends documenting objective cognitive performance using validated instruments, preferably the Montreal Cognitive Assessment (MoCA) for mild dementia or the Mini-Mental State Examination (MMSE) for moderate dementia 17, 18
The National Institute on Aging suggests using the Pfeffer Functional Activities Questionnaire (FAQ) or Disability Assessment for Dementia (DAD) to assess and document functional impairment with input from both patient and informant 17
The American Psychiatric Association recommends obtaining and documenting corroborative history from a reliable informant using standardized tools such as the AD8, IQCODE, or ECog 17, 19

Risk Factors and Comorbidities

The American Heart Association notes that risk factors for dementia include stroke/TIA, depression, sleep apnea, metabolic disorders, delirium, head injury, and Parkinson's disease 18, 20

Diagnostic Accuracy

Combining cognitive tests with functional screens and informant reports significantly improves case-finding accuracy 19

Common Pitfalls to Avoid

Relying solely on patient self-report without informant corroboration leads to missed diagnoses due to lack of insight 17, 19
Failing to use standardized, validated instruments reduces diagnostic accuracy and makes longitudinal tracking unreliable 17

Guidelines for Evaluation and Management of Cognitive Decline

Clinical Assessment

Obtain reliable informant information about changes in cognition, function, and behavior; this information has prognostic significance and is mandatory for accurate diagnosis. 21
Use structured informant‑based tools such as AD‑8, IQCODE, ECog, Lawton Instrumental Activities of Daily Living Scale, or SCD‑Q part 2 to corroborate the patient’s history. 21
Screen for depression (PHQ‑2/PHQ‑9), anxiety (GAD‑7), and neuropsychiatric symptoms (NPI‑Q or MBI‑C) as part of the baseline evaluation. 21
Assess sleep quality and specifically screen for sleep deprivation and obstructive sleep apnea. 22

Cognitive Testing

Use the Montreal Cognitive Assessment (MoCA) when mild cognitive impairment (MCI) is suspected or when MMSE scores are ≥ 24/30 but clinical suspicion remains; MoCA is more sensitive than MMSE for detecting MCI. 22
For moderate dementia screening, the Mini‑Mental State Examination (MMSE) remains acceptable with high sensitivity and specificity. 22
Add the Clock Drawing Test as a supplementary assessment to either MoCA or MMSE. 22
For rapid office screening when time is limited, employ combinations such as MIS + Clock Drawing, Mini‑Cog, AD‑8, or GPCOG. 22

Functional Assessment

Apply structured functional scales such as the Pfeffer Functional Activities Questionnaire (FAQ) or the Disability Assessment for Dementia (DAD) to objectively assess functional autonomy. 22
The key distinction between MCI and dementia rests on whether cognitive changes significantly interfere with daily functioning. 23

Categorization and Management

Subjective Cognitive Decline (SCD)

If cognitive testing is normal but the patient reports persistent concerns, complete the standard dementia workup to identify reversible causes. 21
When the informant reports no observable changes, provide reassurance and arrange follow‑up if deterioration occurs. 21
If the informant confirms changes despite normal testing, schedule annual follow‑ups and consider referral to a memory clinic for detailed neuropsychological testing. 21

Mild Cognitive Impairment (MCI)

Document the impaired cognitive domain(s); memory impairment is the most common predictor of progression to Alzheimer’s dementia. 23
Establish a baseline with formal neuropsychological testing when feasible. 24
Schedule follow‑up every 6–12 months with serial cognitive assessments to monitor for progression. 21
Address modifiable risk factors by treating depression, optimizing sleep, and managing vascular risk factors. 22

Dementia

Use the MMSE as the primary tool for tracking cognitive changes over time. 21
Implement a multidimensional monitoring approach that assesses cognition, functional autonomy, behavioral symptoms, and caregiver burden at least annually. 21
Patients with prominent behavioral symptoms should be reassessed more frequently (every 3–6 months). 21

Longitudinal Monitoring Strategy

Combine cognitive testing with functional screens and informant reports at each visit; this combination significantly improves diagnostic accuracy. 22
Do not rely on a single tool or clinical domain for tracking disease progression. 21
Schedule clinic visits every 6–12 months for stable patients and every 3–6 months for those with behavioral symptoms or unclear diagnoses. 21
Serial assessments help distinguish static conditions from progressive neurodegenerative disease. 21

Evaluation and Management of Subjective Cognitive Decline (SCD)

Epidemiology

SCD is reported by 20‑30 % of individuals who attend memory‑clinic assessments, despite normal objective cognitive testing. 25

Predictive Value of SCD

The ability of SCD to forecast progression to objective cognitive impairment or dementia is limited, with pooled odds ratios ranging from 1.5 to 3.0; most people with SCD will not develop dementia. 26
Among cognitively unimpaired adults, the presence of subjective cognitive complaints does not correspond to differences in Alzheimer‑disease biomarker profiles (e.g., amyloid PET, CSF). 25

Common Reversible Contributors to Subjective Cognitive Concerns

Anxiety and depression are the most frequent reversible causes of SCD. 26
Fatigue and sleep disturbances—including untreated obstructive sleep apnea—can generate subjective memory worries. 25
Attention‑deficit symptoms may be misinterpreted as memory loss. 26
Medication side effects, particularly from anticholinergic agents, can produce perceived cognitive decline. 25
Worry about family history or results of direct‑to‑consumer genetic testing (e.g., APOE) often fuels SCD. 26

Diagnostic Approach

Importance of Informant Information

Obtaining reliable informant reports about changes in cognition, daily function, and behavior is the single most important diagnostic step and carries critical prognostic significance. 27
If the informant observes no measurable changes, the patient’s subjective concerns are highly unlikely to reflect true dementia. 27

Standard Work‑up for Reversible Causes

A systematic medication review to identify agents with anticholinergic or other cognitive‑impairing properties should be performed in all patients with persistent SCD and normal testing. 25

Biomarker Testing Recommendations

Routine ordering of amyloid PET or cerebrospinal‑fluid biomarker studies in cognitively normal individuals with SCD is not recommended. 26
Evidence indicates that biomarker testing in this population cannot reliably predict short‑ or medium‑term cognitive decline, incurs high financial and procedural costs, and may cause psychological harm by labeling individuals with “preclinical disease.” 25

Heterogeneity and Risk Stratification

Predictive accuracy improves only when (a) concerns are corroborated by an informant, (b) subtle objective cognitive changes are present, and (c) there are no comorbid psychiatric symptoms; otherwise, the predictive value of SCD remains low and nonspecific. 26

Psychological Impact of Diagnostic Labeling

The overall risk of severe psychological distress (e.g., suicide attempts) after a dementia diagnosis disclosure is very low (<0.1 %), but catastrophic reactions can occur when individuals are labeled based solely on biomarker positivity without clinical symptoms. 28

All statements are supported by the cited literature.